Skip to main content
. 2020 Aug 18;15(8):e0232917. doi: 10.1371/journal.pone.0232917

Fig 7. Combination of sunitinib with cRGDfK shows enhanced inhibitory effects on cell viability and TGF-β1-induced EMT expression.

Fig 7

(A) A549 cells were treated with sunitinib or a combination of sunitinib plus cRGDfK for 24 h before measuring cell viability. Data represent mean ± SD. *p < 0.01 vs. sunitinib-free controls. (B) Serum-deprived A549 cells were pretreated for 3 h with sunitinib (3 μM) and cRGDfK (10 μM) individually or in combination, and then incubated with TGF-β1 (5 ng/mL) for 72 h. The expression of EMT markers was measured by Western blot. Actin was used as a loading control. (C‒G) A549 cells were pretreated with sunitinib or a combination of sunitinib plus cRGDfK for 3 h and incubated with TGF-β1 (5 ng/mL) for 48 h (C‒E) or 1 h (F and G). The mRNA expression of the indicated genes was measured by qRT-PCR using GAPDH as an internal control. Experiments were performed in triplicate. Data represent the mean ± SD of raw results. # p < 0.01 versus control, * p < 0.05, ** p < 0.01 versus treatment with TGF-β1 only.